Giuseppe Pantaleo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8929064/publications.pdf

Version: 2024-02-01

161	15,344	38742 50	18647 119
papers	citations	h-index	g-index

174	174	174	14181
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature, 1993, 362, 355-358.	27.8	1,837
2	The Immunopathogenesis of Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1993, 328, 327-335.	27.0	1,049
3	Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature, 2001, 410, 106-111.	27.8	910
4	Studies in Subjects with Long-Term Nonprogressive Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1995, 332, 209-216.	27.0	717
5	Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. Journal of Experimental Medicine, 2013, 210, 143-156.	8.5	581
6	The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. PLoS Pathogens, 2015, 11, e1005142.	4.7	445
7	Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nature Medicine, 2004, 10, 806-810.	30.7	426
8	PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nature Medicine, 2016, 22, 754-761.	30.7	388
9	Dominant TNF-Î±+ Mycobacterium tuberculosisâ€“specific CD4+ T cell responses discriminate between latent infection and active disease. Nature Medicine, 2011, 17, 372-376.	30.7	380
10	Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1â€“infected subjects with progressive disease: changes after antiretroviral therapy. Blood, 2004, 103, 966-972.	1.4	345
11	Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 in Primary Infection and Longâ€Termâ€Nonprogressive Infection. Journal of Infectious Diseases, 1997, 176, 924-932.	4.0	311
12	HIV-1-specific IFN-Î³/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7239-7244.	7.1	277
13	An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. Journal of Experimental Medicine, 2008, 205, 63-77.	8.5	273
14	Functional Heterogeneity of Memory CD4 T Cell Responses in Different Conditions of Antigen Exposure and Persistence. Journal of Immunology, 2005, 174, 1037-1045.	0.8	271
15	Functional signatures of protective antiviral Tâ€cell immunity in human virus infections. Immunological Reviews, 2006, 211, 236-254.	6.0	256
16	COMPASS identifies T-cell subsets correlated with clinical outcomes. Nature Biotechnology, 2015, 33, 610-616.	17.5	232
17	Tâ€cell exhaustion in HIV infection. Immunological Reviews, 2019, 292, 149-163.	6.0	217
18	IL-2â€“ and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. Journal of Allergy and Clinical Immunology, 2009, 123, 758-762.	2.9	211

#	Article	IF	Citations
19	Standardization of cytokine flow cytometry assays. BMC Immunology, 2005, 6, 13.	2.2	203
20	Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. Journal of Virology, 2021, 95, .	3.4	200
21	Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nature Medicine, 2000, 6, 762-768.	30.7	192
22	Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nature Reviews Immunology, 2006, 6, 417-423.	22.7	190
23	Immune correlates of vaccine protection against HIV-1 acquisition. Science Translational Medicine, 2015, 7, 310rv7.	12.4	179
24	Mycobacterium tuberculosisâ€specific CD8⁺ T cells are functionally and phenotypically different between latent infection and active disease. European Journal of Immunology, 2013, 43, 1568-1577.	2.9	172
25	Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. European Journal of Immunology, 2004, 34, 3525-3533.	2.9	169
26	Activation of a dendritic cellâ€“T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. Journal of Experimental Medicine, 2008, 205, 2717-2725.	8.5	153
27	Limited CD4+ T-cell renewal in early HIV-1 infection: Effect of highly active antiretroviral therapy. Nature Medicine, 1998, 4, 794-801.	30.7	151
28	Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain, 2008, 131, 1712-1721.	7.6	150
29	Polyfunctional HCVâ€specific Tâ€cell responses are associated with effective control of HCV replication. European Journal of Immunology, 2008, 38, 2665-2677.	2.9	138
30	Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. Science Translational Medicine, 2017, 9, .	12.4	135
31	Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: Implications for antiviral therapy. Nature Medicine, 1998, 4, 341-345.	30.7	129
32	Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 7131-7136.	7.1	121
33	Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16233-16238.	7.1	118
34	Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders. Journal of Experimental Medicine, 2014, 211, 2033-2045.	8.5	108
35	Distinct Profiles of Cytotoxic Granules in Memory CD8 T Cells Correlate with Function, Differentiation Stage, and Antigen Exposure. Journal of Virology, 2009, 83, 2862-2871.	3.4	104
36	Functional Avidity: A Measure to Predict the Efficacy of Effector T Cells?. Clinical and Developmental Immunology, 2012, 2012, 1-14.	3.3	101

#	Article	IF	Citations
37	Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4Ã—: a phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2014, 14, 291-300.	9.1	100
38	Analysis of HIV-1â€“ â€‰and CMV-specific memory CD4 T-cell responses during primary and chronic infection. Blood, 2002, 100, 1381-1387.	1.4	97
39	Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity. Vaccine, 2007, 25, 2120-2127.	3.8	96
40	EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine, 2008, 26, 3162-3174.	3.8	89
41	Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurology, The, 2010, 9, 264-272.	10.2	86
42	Intrathecal immune responses to EBV in early MS. European Journal of Immunology, 2010, 40, 878-887.	2.9	83
43	Distribution and functional analysis of memory antiviral CD8 T cell responses in HIV-1 and cytomegalovirus infections. European Journal of Immunology, 2002, 32, 3756-3764.	2.9	79
44	Combined Use of Mycobacterium tuberculosisâ€“Specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of Active Tuberculosis. Clinical Infectious Diseases, 2015, 60, 432-437.	5.8	75
45	Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine, 2011, 29, 8309-8316.	3.8	70
46	Poxvirus vector-based HIV vaccines. Current Opinion in HIV and AIDS, 2010, 5, 391-396.	3.8	68
47	A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma. Science Translational Medicine, 2021, 13, .	12.4	68
48	Antibodies to combat viral infections: development strategies and progress. Nature Reviews Drug Discovery, 2022, 21, 676-696.	46.4	68
49	The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients. Nature Communications, 2021, 12, 4888.	12.8	67
50	Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy. Aids, 2000, 14, 1887-1897.	2.2	64
51	CCR2 Polymorphism and HIV Disease. Nature Medicine, 1998, 4, 252-253.	30.7	63
52	Differences in HCV-specific T cell responses between chronic HCV infection and HIV/HCV co-infection. European Journal of Immunology, 2005, 35, 3493-3504.	2.9	57
53	Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01. Cell Host and Microbe, 2019, 26, 623-637.e8.	11.0	56
54	TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs. Journal of Clinical Investigation, 2018, 128, 4387-4396.	8.2	55

#	Article	IF	Citations
55	EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine, 2008, 26, 3153-3161.	3.8	54
56	Reactivation of IgA vasculitis after COVID-19 vaccination. Lancet Rheumatology, The, 2021, 3, e617.	3.9	54
57	Implementing SARS-CoV-2 Rapid Antigen Testing in the Emergency Ward of a Swiss University Hospital: The INCREASE Study. Microorganisms, 2021, 9, 798.	3.6	51
58	The moving target: mechanisms of HIV persistence during primary infection. Trends in Immunology, 1999, 20, 446-450.	7.5	48
59	HIV Infection Functionally Impairs Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses. Journal of Virology, 2019, 93, .	3.4	48
60	Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients. JAMA Oncology, 2022, 8, e220446.	7.1	48
61	Proliferation Capacity and Cytotoxic Activity Are Mediated by Functionally and Phenotypically Distinct Virus-Specific CD8 T Cells Defined by Interleukin-7Rî± (CD127) and Perforin Expression. Journal of Virology, 2010, 84, 3868-3878.	3.4	46
62	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. Journal of Virology, 2018, 92, .	3.4	46
63	Early and Prolonged Antiretroviral Therapy Is Associated with an HIV-1-Specific T-Cell Profile Comparable to That of Long-Term Non-Progressors. PLoS ONE, 2011, 6, e18164.	2.5	46
64	The complex challenges of HIV vaccine development require renewed and expanded global commitment. Lancet, The, 2020, 395, 384-388.	13.7	44
65	Accumulation of human immunodeficiency virus-specific cytotoxic T lymphocytes away from the predominant site of virus replication during primary infection. European Journal of Immunology, 1997, 27, 3166-3173.	2.9	43
66	Immune response to HIV. Current Opinion in HIV and AIDS, 2013, 8, 1.	3.8	43
67	Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. Lancet HIV,the, 2019, 6, e737-e749.	4.7	43
68	Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. Journal of Virology, 2015, 89, 8643-8650.	3.4	42
69	Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: A randomized controlled trial. Vaccine, 2018, 36, 6163-6169.	3.8	42
70	Targeted Immune Interventions for an HIV-1 Cure. Trends in Molecular Medicine, 2017, 23, 945-961.	6.7	41
71	Therapeutic vaccines and immunological intervention in HIV infection. Current Opinion in HIV and AIDS, 2016, 11, 576-584.	3.8	40
72	Functional and phenotypic characterizationof tetanus toxoid-specific human CD4+ T cellsfollowing re-immunization. European Journal of Immunology, 2007, 37, 1129-1138.	2.9	39

#	Article	IF	Citations
73	A highly potent antibody effective against SARS-CoV-2 variants of concern. Cell Reports, 2021, 37, 109814.	6.4	39
74	Selective pressure exerted by immunodominant HIV-1-specific cytotoxic T lymphocyte responses during primary infection drives genetic variation restricted to the cognate epitope. European Journal of Immunology, 1999, 29, 3629-3635.	2.9	38
75	Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count. Aids, 2000, 14, 2257-2263.	2.2	38
76	CD32 ⁺ and PD-1 ⁺ Lymph Node CD4 T Cells Support Persistent HIV-1 Transcription in Treated Aviremic Individuals. Journal of Virology, 2018, 92, .	3.4	38
77	HLA-B7â€“Restricted EBV-Specific CD8+ T Cells Are Dysregulated in Multiple Sclerosis. Journal of Immunology, 2012, 188, 4671-4680.	0.8	36
78	Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTUÂ®-Multi-HIVB, in untreated HIV-1 infected subjects. Vaccine, 2012, 30, 4046-4054.	3.8	36
79	DNA/NYVAC Vaccine Regimen Induces HIV-Specific CD4 and CD8 T-Cell Responses in Intestinal Mucosa. Journal of Virology, 2011, 85, 9854-9862.	3.4	35
80	Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. Journal of Virology, 2015, 89, 8525-8539.	3.4	35
81	Clinically-relevant threshold of preformed donor-specific anti-HLA antibodies in kidney transplantation. Human Immunology, 2016, 77, 483-489.	2.4	35
82	Encephalopathies Associated With Severe COVID-19 Present Neurovascular Unit Alterations Without Evidence for Strong Neuroinflammation. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	34
83	NYVAC immunization induces polyfunctional HIVâ€specific Tâ€cell responses in chronicallyâ€infected, ARTâ€treated HIV patients. European Journal of Immunology, 2012, 42, 3038-3048.	2.9	30
84	Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C. PLoS ONE, 2012, 7, e35485.	2.5	30
85	Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles. Journal of Virology, 2015, 89, 970-988.	3.4	30
86	Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens. PLoS ONE, 2012, 7, e48524.	2.5	30
87	Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses. Journal of Virology, 2017, 91, .	3.4	29
88	Mixed Th1 and Th2 Mycobacterium tuberculosis-specific CD4 T cell responses in patients with active pulmonary tuberculosis from Tanzania. PLoS Neglected Tropical Diseases, 2017, 11, e0005817.	3.0	29
89	DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. Journal of Clinical Investigation, 2019, 129, 4769-4785.	8.2	27
90	NFÎºB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1333-E1342.	7.1	26

#	Article	IF	Citations
91	HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. Journal of Virology, 2017, 91, .	3.4	26
92	The Number of Toll-Like Receptor 9-Agonist Motifs in the Adenovirus Genome Correlates with Induction of Dendritic Cell Maturation by Adenovirus Immune Complexes. Journal of Virology, 2012, 86, 6279-6285.	3.4	25
93	Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. Journal of Virology, 2019, 93, .	3.4	25
94	Tumor suppression of novel antiâ€“PD-1 antibodies mediated through CD28 costimulatory pathway. Journal of Experimental Medicine, 2019, 216, 1525-1541.	8.5	23
95	Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. Journal of Virology, 2016, 90, 4133-4149.	3.4	22
96	Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques. Nature Communications, 2021, 12, 5215.	12.8	22
97	Vaccine and immunotherapeutic interventions. Current Opinion in HIV and AIDS, 2013, 8, 236-242.	3.8	21
98	Functional patterns of HIV-1-specific CD4 T-cell responses in children are influenced by the extent of virus suppression and exposure. Aids, 2007, 21, 23-30.	2.2	20
99	Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination. PLoS ONE, 2019, 14, e0225622.	2.5	20
100	Emerging single-cell technologies in immunology. Journal of Leukocyte Biology, 2015, 98, 23-32.	3.3	19
101	TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice. PLoS Pathogens, 2020, 16, e1009025.	4.7	19
102	Antigenic competition in CD4 ⁺ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. Science Translational Medicine, 2019, 11, .	12.4	18
103	Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland. Open Forum Infectious Diseases, 2021, 8, ofab149.	0.9	18
104	A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response. Vaccine, 2008, 26, 4006-4014.	3.8	17
105	Independent Evolution of Hypervariable Regions of HIV-1 gp120: V4 as a Swarm of N-Linked Glycosylation Variants. AIDS Research and Human Retroviruses, 2008, 24, 106-113.	1.1	17
106	Unraveling the strands of HIV's web. Nature Medicine, 1999, 5, 27-28.	30.7	16
107	Lymph node migratory dendritic cells modulate HIV-1 transcription through PD-1 engagement. PLoS Pathogens, 2019, 15, e1007918.	4.7	16
108	Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 Î±-chain (CD11a) in MS patients. Multiple Sclerosis Journal, 2014, 20, 837-842.	3.0	15

#	Article	IF	Citations
109	Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8+ T lymphocyte exhaustion. BMC Biotechnology, 2019, 19, 67.	3.3	15
110	Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein. Clinical Infectious Diseases, 2020, 72, 50-60.	5.8	15
111	Detection of antisense protein (ASP) RNA transcripts in individuals infected with human immunodeficiency virus type 1 (HIV-1). Journal of General Virology, 2019, 100, 863-876.	2.9	15
112	Sampling lymphoid tissue cells by ultrasound-guided fine needle aspiration of lymph nodes in HIV-infected patients. Aids, 1999, 13, 1503-1509.	2.2	13
113	Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. Journal of Virology, 2019, 93, .	3.4	13
114	Long sequence duplications, repeats, and palindromes in HIV-1 gp120: Length variation in V4 as the product of misalignment mechanism. Virology, 2010, 399, 167-175.	2.4	12
115	Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial. EBioMedicine, 2017, 24, 195-204.	6.1	12
116	In Situ Characterization of Follicular Helper CD4 T Cells Using Multiplexed Imaging. Frontiers in Immunology, 2020, 11, 607626.	4.8	12
117	A case for preART-adjusted endpoints in HIV therapeutic vaccine trials. Vaccine, 2016, 34, 1282-1288.	3.8	11
118	Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial. PLoS Pathogens, 2020, 16, e1008522.	4.7	11
119	Acquisition of optimal TFH cell function is defined by specific molecular, positional, and TCR dynamic signatures. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	11
120	The multi-faceted personality of HIV. Nature Medicine, 1997, 3, 1318-1320.	30.7	10
121	HIVâ€1â€Specific Immune Response. Advances in Pharmacology, 2008, 56, 75-92.	2.0	10
122	The Polymorphic Nature of HIV Type 1envV4 Affects the Patterns of Potential N-Glycosylation Sites in Proviral DNA at the Intrahost Level. AIDS Research and Human Retroviruses, 2009, 25, 199-206.	1.1	10
123	Interleukin-1- and Type I Interferon-Dependent Enhanced Immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef Vaccine Vector with Dual Deletions of Type I and Type II Interferon-Binding Proteins. Journal of Virology, 2015, 89, 3819-3832.	3.4	10
124	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. Journal of Virology, 2018, 92, .	3.4	10
125	SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study. BMJ Open, 2021, 11, e049232.	1.9	10
126	Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses. Frontiers in Immunology, 2019, 10, 2941.	4.8	9

#	Article	IF	Citations
127	Comparative analysis and generation of a robust HIV-1 DNA quantification assay. Journal of Virological Methods, 2019, 263, 24-31.	2.1	9
128	Anti-SARS-CoV-2 Titers Predict the Severity of COVID-19. Viruses, 2022, 14, 1089.	3.3	9
129	Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption. PLoS ONE, 2019, 14, e0210965.	2.5	8
130	A Robust Method for Assaying the Immunoreactive Fraction in Nonequilibrium Systems. Pharmaceuticals, 2019, 12, 177.	3.8	8
131	Inter-Laboratory Reproducibility of Inducible HIV-1 Reservoir Quantification by TILDA. Viruses, 2020, 12, 973.	3.3	8
132	Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. PLoS Medicine, 2020, 17, e1003117.	8.4	8
133	Severe post-EBV encephalopathy associated with myelin oligodendrocyte glycoprotein-specific immune response. Journal of Neuroimmunology, 2007, 192, 192-197.	2.3	7
134	Hyperglycaemia is inversely correlated with live M. bovis BCGâ€specific CD4⁺ T cell responses in Tanzanian adults with latent or active tuberculosis. Immunity, Inflammation and Disease, 2018, 6, 345-353.	2.7	7
135	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. Npj Vaccines, 2021, 6, 56.	6.0	7
136	A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial. Journal of Virology, 2021, 95, .	3.4	6
137	Three-Year Immune Reconstitution in PI-Sparing and PI-Containing Antiretroviral Regimens in Advanced HIV-1 Disease. Antiviral Therapy, 2007, 12, 553-558.	1.0	6
138	A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles. Virology, 2017, 507, 242-256.	2.4	5
139	Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions. Lancet HIV,the, 2019, 6, e334-e340.	4.7	5
140	Clinical studies of experimental vaccines. Current Opinion in HIV and AIDS, 2006, 1, 286-293.	3.8	4
141	Cytokine mRNA profile of Epsteinâ€“Barr virus-stimulated highly differentiated T cells in multiple sclerosis: A pilot study. Journal of Neuroimmunology, 2010, 225, 167-170.	2.3	4
142	MOBP-specific cellular immune responses are weaker than MOG-specific cellular immune responses in patients with multiple sclerosis and healthy subjects. Neurological Sciences, 2013, 34, 539-543.	1.9	4
143	Human macrophages and monocyte-derived dendritic cells stimulate the proliferation of endothelial cells through midkine production. PLoS ONE, 2022, 17, e0267662.	2.5	4
144	Introduction: Recent advances in the pathogenesis of human immunodeficiency virus infection. Seminars in Immunopathology, 1997, 18, 253-256.	4.0	3

#	Article	IF	Citations
145	Modulation of human memory Tâ€cell function by different antigenâ€presenting cells. European Journal of Immunology, 2012, 42, 799-802.	2.9	3
146	Detection of Human Immunodeficiency Virus Type 1 (HIV-1) Antisense Protein (ASP) RNA Transcripts in Patients by Strand-Specific RT-PCR. Journal of Visualized Experiments, 2019, , .	0.3	3
147	Case Report: A Rare Truncating Variant of the CFHR5 Gene in IgA Nephropathy. Frontiers in Genetics, 2021, 12, 529236.	2.3	3
148	High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus. Clinical Microbiology and Infection, 2022, 28, 611.e1-611.e7.	6.0	3
149	Understanding what makes a goodversus a bad vaccine. European Journal of Immunology, 2005, 35, 2528-2531.	2.9	2
150	Systems biology in the development of HIV vaccines. Current Opinion in HIV and AIDS, 2012, 7, 44-49.	3.8	2
151	A Highly Potent Antibody Effective Against SARS-CoV-2 Variants of Concern. SSRN Electronic Journal, 0, , .	0.4	2
152	Eculizumab as a New Treatment for Severe Acute Post-infectious Glomerulonephritis: Two Case Reports. Frontiers in Medicine, 2021, 8, 663258.	2.6	2
153	The Immunopathogenesis of HIV-1 Infection. , 2017, , 837-845.e3.		1
154	Case Report: SARS-CoV-2 as an unexpected causal agent of isolated febrile hepatitis. F1000Research, 2021, 10, 400.	1.6	1
155	Case Report: SARS-CoV-2 as an unexpected causal agent of predominant febrile hepatitis. F1000Research, 0, 10, 400.	1.6	1
156	Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials. PLoS Pathogens, 2021, 17, e1010016.	4.7	1
157	Nonrandom Distribution of Cryptic Repeating Triplets of Purines and Pyrimidines (RNY)_nin gp120 of HIV Type1. AIDS Research and Human Retroviruses, 2012, 28, 493-504.	1.1	0
158	Antibodies to Chlamydia trachomatis and reproductive health issues in women with SLE: a caseâ€“control study. Lupus Science and Medicine, 2018, 5, e000293.	2.7	0
159	Safety and tolerance of lymph node biopsies from chronic HIV-1 volunteers in rural Tanzania. BMC Research Notes, 2019, 12, 561.	1.4	0
160	SAT0205â€…A CYTOKINE â€œSCAR SIGNATUREâ€•CHARACTERIZES PATIENTS WITH FATIGUE IN SYSTEMIC LUPUS ERYTHEMATOSUS AND SJOGRENâ€™S SYNDROME. , 2019, , .		0
161	The immunopathogenesis of HIV-1 infection. , 2010, , 944-953.		0